Morten Olesen

Medicine & Life Sciences

1. Denmark 100%
2. Atrial Fibrillation 68%
3. mirabegron 64%
4. Prescriptions 63%
5. Overactive Urinary Bladder 48%
6. Muscarinic Antagonists 47%
7. aclidinium bromide 35%
8. Anticoagulants 35%
9. Case-Control Studies 32%
10. Dicloxacillin 32%
11. Stroke 32%
12. Confidence Intervals 32%
13. Drug Utilization 31%
14. Lip Neoplasms 30%
15. Floxacillin 30%
16. Meta-Analysis 28%
17. Randomized Controlled Trials 27%
18. Formoterol Fumarate 27%
19. Multimorbidity 26%
20. Quetiapine Fumarate 25%
21. Hydrochlorothiazide 24%
22. Databases 24%
23. Therapeutics 22%
24. Population 22%
25. Platelet Aggregation Inhibitors 21%
26. Heart Valves 21%
27. General Practitioners 21%
28. Gadolinium 21%
29. Myocardial Infarction 20%
30. Warfarin 20%
31. Systematic Reviews 19%
32. Embolism 19%
33. Germany 19%
34. Mortality 19%
35. Angiotensin-Converting Enzyme Inhibitors 19%
36. Hydroxymethylglutaryl-CoA Reductase Inhibitors 18%
37. Cohort Studies 18%
38. Chronic Obstructive Pulmonary Disease 17%
39. Opioid Analgesics 17%
40. Observational Studies 16%
41. Multicenter Studies 16%
42. Placebos 16%
43. Mineralocorticoid Receptor Antagonists 15%
44. Comorbidity 15%
45. Vaccines 14%
46. Registries 14%
47. Heart Failure 14%
48. Hemorrhage 14%
49. Odds Ratio 13%
50. Pharmaceutical Preparations 13%